Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®

TORONTO, May 1, 2026 /PRNewswire/ – Apotex Inc. ("Apotex" or the "Company"), Canada's largest Canadian‑based global health company, today announced that Health Canada has approved Apo‑Semaglutide Injection, a generic equivalent of Ozempic® (semaglutide injection). As the first Canadian‑based pharmaceutical company to gain authorization for a generic equivalent of Ozempic®, this approval reinforces Apotex's leadership in bringing high‑quality, affordable alternatives to…

Key Insights

• This topic is currently trending
• Experts are closely monitoring developments
• It may impact future decisions